Meeting
2022 ASCO Annual Meeting
Tumor agnostic efficacy of selpercatinib in patients with RET fusion+ solid tumors: A global, multicenter, registrational trial update (LIBRETTO-001).
Authors
Vivek Subbiah
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Vivek Subbiah , Juergen Wolf , Bhavana Konda , Hyunseok Kang , Alexander I. Spira , Jared Weiss , Masayuki Takeda , Yuichiro Ohe , Saad A. Khan , Kadoaki Ohashi , Victoria Soldatenkova , Sylwia Szymczak , Loretta Sullivan , Jennifer Wright , Alexander E. Drilon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT03157128
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3094)
DOI
10.1200/JCO.2022.40.16_suppl.3094
Abstract #
3094
Poster Bd #
86
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Durable efficacy of selpercatinib in patients with RET fusion+ solid tumors, with a focus on GI tumors: LIBRETTO-001.
First Author: Vivek Subbiah
Poster
2021 ASCO Annual Meeting
Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC).
First Author: Benjamin Besse
Poster
2021 ASCO Annual Meeting
Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update.
First Author: Eric Jeffrey Sherman
Poster
2020 ASCO Virtual Scientific Program
Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.
First Author: Manisha H. Shah